MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical …
ME Hegi, E Genbrugge, T Gorlia, R Stupp… - Clinical Cancer …, 2019 - AACR
Purpose: The methylation status of the O6-methylguanine DNA methyltransferase (MGMT)
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.
ME Hegi, E Genbrugge, T Gorlia, R Stupp… - Clinical cancer research …, 2019 - sonar.ch
RESULTS For 4,041 patients valid MGMT results were obtained, whereof 1,725 were
randomized. The unsupervised cutoff in the training dataset was 1.27 (log2 [1,000×(MGMT+ …
randomized. The unsupervised cutoff in the training dataset was 1.27 (log2 [1,000×(MGMT+ …
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical Trials
ME Hegi, E Genbrugge, T Gorlia, R Stupp… - Clinical Cancer …, 2019 - zora.uzh.ch
PURPOSE The methylation status of the O6-methylguanine DNA methyltransferase (MGMT)
gene promoter is predictive for benefit from temozolomide in glioblastoma. A clinically …
gene promoter is predictive for benefit from temozolomide in glioblastoma. A clinically …
[PDF][PDF] MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical …
ME Hegi, E Genbrugge, T Gorlia, R Stupp, MR Gilbert… - 2019 - scholar.archive.org
PURPOSE The methylation status of the O6-methylguanine DNA methyltransferase (MGMT)
gene promoter is predictive for benefit from temozolomide in glioblastoma. A clinically …
gene promoter is predictive for benefit from temozolomide in glioblastoma. A clinically …
MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials
ME Hegi, E Genbrugge, T Gorlia, R Stupp… - CLINICAL CANCER …, 2019 - biblio.ugent.be
Purpose: The methylation status of the O-6-methylguanine DNA methyltransferase (MGMT)
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
[PDF][PDF] MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical …
ME Hegi, E Genbrugge, T Gorlia, R Stupp… - Clinical cancer …, 2019 - serval.unil.ch
The methylation status of the O 6-methylguanine DNA methyltransferase (MGMT) gene
promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
[HTML][HTML] MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four …
ME Hegi, E Genbrugge, T Gorlia, R Stupp… - … cancer research: an …, 2019 - ncbi.nlm.nih.gov
Purpose: The methylation status of the O 6-methylguanine DNA methyltransferase (MGMT)
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
[PDF][PDF] MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical …
ME Hegi, E Genbrugge, T Gorlia, R Stupp, MR Gilbert… - academia.edu
Purpose: The methylation status of the O6-methylguanine DNA methyltransferase (MGMT)
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical …
ME Hegi, E Genbrugge, T Gorlia, R Stupp… - … Cancer Research: an …, 2018 - europepmc.org
Purpose The methylation status of the O 6-methylguanine DNA methyltransferase (MGMT)
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.
ME Hegi, E Genbrugge, T Gorlia, R Stupp… - … cancer research: an …, 2019 - folia.unifr.ch
RESULTS For 4,041 patients valid MGMT results were obtained, whereof 1,725 were
randomized. The unsupervised cutoff in the training dataset was 1.27 (log2 [1,000×(MGMT+ …
randomized. The unsupervised cutoff in the training dataset was 1.27 (log2 [1,000×(MGMT+ …